Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Merck to buy Prometheus Bio....

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Apr 17, 2023 6:25am

139 Views

Post# 35397877

RE:RE:RE:RE:RE:RE:Merck to buy Prometheus Bio....

All good comments from you Westcoast. Thank you for your work and good writing. I can understand almost everything! For some here like me, the frustrations are coming probably from how they play the game right now. No NR for months as a result the SP is probably manipulated down and ask during that time a bunch of new very cheap options. Still believe a deal will come this year and will not sell before. GL

<< Previous

Bullboard Posts

Next >>

Anaergia expands relationship with PepsiCo